Workflow
科创50增强ETF(588460)
icon
Search documents
科创50增强ETF(588460)开盘涨0.25%,重仓股海光信息涨0.20%,中芯国际涨0.95%
Xin Lang Cai Jing· 2025-10-21 01:44
Core Viewpoint - The article discusses the performance of the Kexin 50 Enhanced ETF (588460), highlighting its recent market activity and key holdings, as well as its performance metrics since inception. Group 1: ETF Performance - Kexin 50 Enhanced ETF (588460) opened with a gain of 0.25%, priced at 1.618 yuan [1] - Since its inception on December 1, 2022, the fund has achieved a return of 61.44% [1] - The fund's return over the past month is reported at 1.06% [1] Group 2: Key Holdings - Major stocks in the Kexin 50 Enhanced ETF include: - Haiguang Information: up 0.20% [1] - SMIC: up 0.95% [1] - Cambrian: unchanged [1] - Lanke Technology: up 0.85% [1] - Kingsoft Office: up 0.42% [1] - Sitoway: up 0.02% [1] - Zhongwei Company: up 1.24% [1] - Hengxuan Technology: up 1.11% [1] - Huahai Qingke: up 0.79% [1] - Ninebot: up 0.75% [1] Group 3: Management Information - The Kexin 50 Enhanced ETF is managed by Penghua Fund Management Co., Ltd. [1] - The fund manager is Su Junjie [1]
科创50增强ETF(588460)开盘涨0.87%,重仓股海光信息涨1.82%,中芯国际涨1.82%
Xin Lang Cai Jing· 2025-09-30 01:38
Core Points - The Kexin 50 Enhanced ETF (588460) opened at a price of 1.741 yuan, with an increase of 0.87% [1] - The fund's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board 50 Index [1] - Since its establishment on December 1, 2022, the fund has achieved a return of 73.26%, with a monthly return of 9.70% [1] Stock Performance - Haiguang Information opened with a rise of 1.82% [1] - SMIC (Semiconductor Manufacturing International Corporation) also increased by 1.82% [1] - Cambrian (寒武纪) saw a significant rise of 4.87% [1] - Lanke Technology (澜起科技) increased by 1.50% [1] - Kingsoft Office (金山办公) rose by 1.95% [1] - Sitwei (思特威) had a modest increase of 0.63% [1] - Zhongwei Company (中微公司) experienced a decline of 0.98% [1] - Hengxuan Technology (恒玄科技) decreased by 0.50% [1] - Huahai Qingke (华海清科) fell by 1.11% [1] - Ninebot (九号公司) had a slight increase of 0.06% [1]
科创50增强ETF(588460)开盘跌0.81%,重仓股海光信息跌1.83%,中芯国际跌1.04%
Xin Lang Cai Jing· 2025-09-26 04:33
Group 1 - The core point of the article highlights the performance of the Kexin 50 Enhanced ETF (588460), which opened down 0.81% at 1.718 yuan on September 26 [1] - The major holdings of the Kexin 50 Enhanced ETF include companies such as Haiguang Information, which fell by 1.83%, and SMIC, which decreased by 1.04% [1] - The fund's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board 50 Index, managed by Penghua Fund Management Co., Ltd., with a return of 73.07% since its inception on December 1, 2022, and a return of 15.47% over the past month [1] Group 2 - The article lists the performance of other key stocks within the ETF, including Cambrian, which dropped by 1.56%, and Kingsoft Office, which fell by 1.11% [1] - The ETF's performance reflects broader market trends, as indicated by the declines in several of its major holdings [1] - The article provides a snapshot of the current market conditions affecting the Kexin 50 Enhanced ETF and its constituents [1]
科创50增强ETF(588460)开盘跌0.67%,重仓股海光信息涨0.60%,中芯国际跌1.24%
Xin Lang Cai Jing· 2025-09-11 01:44
Group 1 - The core point of the article highlights the performance of the Kexin 50 Enhanced ETF (588460), which opened down 0.67% at 1.473 yuan on September 11 [1] - The major holdings of the Kexin 50 Enhanced ETF include companies like Haiguang Information, which rose by 0.60%, and SMIC, which fell by 1.24% [1] - The fund's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board 50 Index, managed by Penghua Fund Management Co., Ltd., with a return of 48.16% since its establishment on December 1, 2022, and a return of 21.79% over the past month [1] Group 2 - The article provides specific stock performance details of the ETF's holdings, including notable movements such as Cambrian's increase of 1.73% and Lanke Technology's decrease of 3.59% [1] - The fund manager is Su Junjie, indicating a specific leadership in the management of the ETF [1] - The article emphasizes the importance of monitoring market risks associated with investments, although it does not provide specific risk details [1]
ETF复盘0725-三大指数小幅回调,科创50ETF指数(588040)逆市走强
Sou Hu Cai Jing· 2025-07-25 10:33
Market Overview - On July 25, A-shares experienced slight declines, with the Shanghai Composite Index down by 0.33%, the Shenzhen Component down by 0.22%, and the ChiNext Index down by 0.23% [1] - The main broad-based indices showed mixed performance, with the Sci-Tech 50 Index rising by 2.07%, while the majority of stocks in the market saw declines, with only about 2,500 stocks advancing [1][2] Sector Performance - In sector performance, the electronics sector led with a gain of 1.37%, followed by the computer sector at 1.26%, and real estate at 0.63%. Conversely, the construction decoration sector fell by 2.06%, construction materials by 1.69%, and food and beverage by 1.65% [8] Key Highlights Sci-Tech Sector - In the first half of the year, over 30% of 5G base stations and gigabit users were reported in China, with the Ministry of Industry and Information Technology emphasizing the need for legislative research in key areas like digital economy and artificial intelligence, indicating a warming of related industrial policies [8] - Recent advancements in the humanoid robot industry have accelerated commercialization, with significant gains in related stocks such as reducers and lightweight materials, positively impacting the Sci-Tech 50 Index [8] - The semiconductor industry is also seeing a boost from strong AI demand, as evidenced by TSMC's financial results, further enhancing the valuation recovery of leading tech stocks in the Sci-Tech board [8] Pharmaceutical Sector - In the first half of the year, China's innovative drug business development (BD) reached a new peak, with over 50 outbound transactions totaling more than $48 billion [9] - Chinese innovative drug assets are gaining global recognition, with clinical data increasingly featured in academic conferences, leading to a rise in BD authorization amounts and numbers [9] - The growing competitiveness of Chinese innovative drugs is expected to result in more BD transactions, with several projects anticipated to enter major global markets in the next 2-3 years, accelerating the globalization of domestic innovative pharmaceutical companies [9]